|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:1030-1038
© 2000 The American Association for Thoracic Surgery
Cardiopulmonary Support And Physiology |
From the Department of Cardiology and Institute of Experimental Clinical Research, Skejby Hospital, Aarhus University Hospitals, University of Aarhus, Denmark.
Supported by the Danish Health Research Council, grant No. 9600822 (Aarhus University, Novo Nordisk Centre for Research in Growth and Regeneration).
Address for reprints: Flemming Randsbæk, MD, Department of Cardiology, Skejby Hospital, Aarhus University Hospitals, Brendstrupgaardvej, 8200 Aarhus N, Denmark.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
We studied whether captopril affects myocardial metabolism during cardioplegic storage, postcardioplegic reperfusion, or both. We hypothesized that captopril may affect glucose-related amino acid metabolism during cardioplegic storage, postcardioplegic reperfusion, or both.
| Materials and methods |
|---|
|
|
|---|
The animals were premedicated with intramuscular midazolam (Dormicum, 0.5 mg/kg) and ketamine (Ketalar, 10 mg/kg) followed by intravenous ketamine (5 mg/kg) before orotracheal intubation. Pigs were anaesthetized with halothane 1% to 2% and placed on positive-pressure ventilation (N2O/O2 mixture 2:1, Engström Respirator System 300; Lab Medical AB, Bromma, Sweden).
After median sternotomy and systemic heparinization (200 U/kg), the pericardium was opened, a vent was introduced into the left ventricle through the left atrial appendage, and both caval veins were clamped. After aortic crossclamping, 1 L of Bretschneiders procaine containing solution No. 3 (sodium, 12 mmol/L; potassium, 10 mmol/L; magnesium, 1 mmol/L; procaine, 7.3 mmol/L; chloride, 31.3 mmol/L; and mannitol, 239 mmol/L; oxygenated solution with 12.5 mL of NaOH added to obtain a pH of 7.4) was infused antegradely through the aortic root. After infusion, the hearts were excised and immersed in 0.5 L of cold (4°C-6°C) heparinized saline solution. The hearts were kept at this temperature during a hypothermic cardioplegic storage (HCS) period of either 6 or 30 hours.
Study series
We compared hearts from control pigs with hearts from captopril-treated pigs in two distinct study series. Hearts were randomized within, but not between, study series.
In one series we studied cardiac hemodynamics and metabolism during 60 minutes of blood reperfusion subsequent to 6 hours of HCS.
Control pigs (n = 8)
After cardioplegic arrest, hearts were excised and subjected to 6 hours of HCS. Subsequently, the hearts were reperfused with blood in a modified Langendorff model.
Captopril-treated pigs (n = 9)
Animals were pretreated with increasing oral doses of captopril (Capoten) for 3 weeks. They received 12.5 mg once a day on day 1, increasing to 37.5 mg 3 times a day on day 7, and thereafter to 50 mg 3 times daily for the remaining 2 weeks. Before the operation, an intravenous bolus of captopril (25 mg) was given. In addition, captopril-containing (1 mg/L) cardioplegic solution was infused before exposure to 6 hours of HCS and subsequent reperfusion with captopril-containing blood (1 mg/L) in the Langendorff model.
In another series we studied myocardial energy stores and metabolites during 30 hours of HCS.
Control pigs (n = 8)
Cardioplegic arrest was induced, and the hearts were subjected to 30 hours of HCS. The hearts were not reperfused.
Captopril-treated pigs (n = 9)
Animals were premedicated with captopril as in the previous study series, and cardioplegic arrest was induced with captopril-containing cardioplegic solution. The hearts were subjected to 30 hours of HCS without subsequent reperfusion.
Reperfusion
Hearts allocated to 6 hours of HCS and 60 minutes of reperfusion
After 6 hours of HCS, the hearts were reperfused in a modified Langendorff perfusion model with blood-Ringer chloride solution (1:1), as previously described.
9,10 The hearts were prepared for reperfusion as described.
9 Electrical defibrillation was performed after 10 minutes of reperfusion because of ventricular fibrillation at the beginning of reperfusion. At this time, the hearts had reached a temperature necessary to obtain regular contractions after defibrillation. Left ventricular function was monitored continuously during reperfusion, and myocardial blood flow and content of oxygen, lactate, glucose, glutamate, and alanine in arterial and coronary sinus blood were measured simultaneously at the start of reperfusion and after 4, 8, 12, 18, 25, 40, and 60 minutes of reperfusion.
Measurements
Left ventricular peak systolic pressure, end-diastolic pressure, and the first derivative of the left ventricular pressure (dP/dt) were recorded continuously during the reperfusion period.
10 Developed left ventricular pressure was calculated as the difference between left ventricular peak systolic pressure and end-diastolic pressure.
Myocardial blood flow was measured directly by collecting the blood perfusate from the right atrium during reperfusion.
Lactate was analyzed in whole blood,
11 and glucose,
12 glutamate, and alanine
13 were analyzed in plasma. Net metabolite flux across the myocardium was calculated as aorta-coronary sinus concentration differences multiplied by myocardial blood flow for whole blood analyses corrected by multiplying metabolite flux with 1 hematocrit for plasma analyses. A negative net flux reflects release, and a positive net flux reflects uptake of a metabolite. Blood oxygen saturation and pressure were measured with a blood gas analyzer (Copenhagen ABL, Copenhagen, Denmark). Myocardial oxygen uptake (in milliliters per minute) was calculated as previously described.
10
Prolonged HCS
Hearts allocated to 30 hours of HCS
During 30 hours of HCS, we harvested transmyocardial biopsy specimens from the anterior wall of the left ventricle by using a Tru-Cut biopsy needle (Baxter Healthcare Corporation, Deerfield, Ill). Samples were obtained at 15 minutes and 1, 3, 6, 12, 18, 22, 24, 27, and 30 hours of HCS.
Measurements
The tissue samples were plunged into liquid nitrogen, and metabolites were extracted by using 500 µL of ice-cold 0.42 mmol/L perchloric acid. The samples were homogenized mechanically on ice-bath with a Teflon pestle and centrifuged at 4°C.
14 Tissue concentrations of lactate,
11 alanine, and glutamate
13 were determined enzymatically in the clear supernatant, as described for the blood samples. High-energy phosphates were analyzed by using high-performance chromatography (Shimadzu, Kyoto, Japan).
14 Tissue glycogen content was determined by using the filter paper technique.
15
Statistical analysis
All results are presented as means ± SD. Data were tested for normality and homogeneity of variance. When statistically insignificant, variables were considered unchanged or unaffected.
Hearts allocated to HCS and reperfusion
Functional variables were compared from 12 minutes of reperfusion when all hearts were beating to the end of reperfusion. Blood flow and glucose, lactate, and oxygen flux were compared from the start to the end of reperfusion. Glutamate and alanine flux were compared from 4 minutes to the end of reperfusion. We used analysis of variance (ANOVA) for repeated measurements with the BMDP computer program 5V ("unbalanced repeated-measures models with structural covariance matrices"; BMDP Software, Los Angeles, Calif). If significant, the post hoc modified t test, according to the method of Bonferroni, was used to localize statistical differences. Glutamate and alanine flux at the start of reperfusion were compared by nonparametric statistics. Correlation between variables was analyzed by linear regression.
Hearts allocated to prolonged HCS
Comparisons were made over 30 hours of HCS by using ANOVA for repeated measurements.
| Results |
|---|
|
|
|---|
Effects of captopril on myocardial function and metabolism during 60 minutes of reperfusion after 6 hours of hypothermic cardioplegic storage
Left ventricular function
Developed left ventricular pressure was increased in captopril-treated hearts during reperfusion (151 ± 16 vs 134 ± 19 mm Hg, P = .02). The same was the case for left ventricular relaxation (dP/dt, 1508 ± 383 vs 1307 ± 384 mm Hg/s, P = .04), whereas captopril decreased heart rate (110 ± 27 vs 133 beats/min, P = .04). We found no differences in rate pressure product (16,610 ± 1652 vs 17,822 ± 1827 mm Hg/min, P = .6), contractility (+dP/dt; 1668 ± 347 vs 1656 ± 346 mm Hg/s, P = .9), or left ventricular end-diastolic pressure (11.9 ± 3.3 vs 11.3 ± 3.4 mm Hg, P = .8) between captopril-treated and control hearts during reperfusion.
Myocardial blood flow
We observed no differences in myocardial blood flow between captopril-treated hearts and control hearts during 60 minutes of reperfusion (Table I).
|
|
Oxygen uptake
Oxygen uptake data is shown in Table I
. At the beginning of reperfusion (0 minutes), we observed no difference in oxygen uptake between captopril-treated and control hearts (18.68 ± 10.15 vs 20.48 ± 5.56 mL/min, P = .3). During the first 4 minutes of reperfusion, however, oxygen uptake increased in captopril-treated hearts (from 18.68 ± 10.15 to 32.61 ± 7.42 mL/min, P = .01), whereas no increase was observed in control hearts (20.48 ± 5.56 vs 20.95 ± 4.49 mL/min, P = .6). During the remaining reperfusion period, the difference in oxygen uptake between captopril-treated and control hearts was maintained (P < .001).
Glutamate release
Captopril increased glutamate release 11-fold at the start of reperfusion (P < .001; Fig 1
and Table I
). Glutamate release declined in both captopril-treated and control hearts from the start to 4 minutes of reperfusion. This was most pronounced in captopril-treated hearts (captopril-treated hearts, from 98.75 ± 53.47 to 2.65 ± 1.70 µmol/min [P < .001], vs control hearts, from 8.69 ± 8.05 to 2.23 ± 2.24 µmol/min [P = .01]).
Alanine release
Captopril increased alanine release 17-fold at the start of reperfusion (P < .001; Table I
). The release pattern was similar in the two groups, but like glutamate, the change in release from the start to 4 minutes of reperfusion was most pronounced in captopril-treated hearts.
Relation between glucose uptake and glutamate release at the start of reperfusion
In captopril-treated hearts there was a linear relationship between glutamate release and glucose uptake (r = 0.66, P = .05). This relationship was not observed in control hearts (Fig 2).
|
Effects of captopril on myocardial content of metabolites during 30 hours of HCS (Table II)
We found no difference in heart weight between captopril-treated hearts and control hearts after 30 hours of HCS (280 ± 31 vs 273 ± 16 g, P = .6).
|
Lactate content
We found no difference in lactate accumulation between captopril-treated and control hearts. In both groups tissue levels of lactate increased during 30 hours of HCS.
Adenosine triphosphate content
Captopril had no effect on myocardial content of adenosine triphosphate during 30 hours of HCS. Tissue adenosine triphosphate content declined continuously during the HCS period.
Glutamate content
We found no differences in myocardial glutamate content between captopril-treated and control hearts. Myocardial levels of glutamate declined during 30 hours of HCS in both groups.
Alanine content
Captopril did not affect myocardial content of alanine during 30 hours of HCS. We observed an increase in tissue alanine content in both captopril-treated and control hearts during storage.
Relation between glucose-related amino acids
In both captopril-treated and control hearts, there was a linear relationship between tissue content of glutamate and alanine (r = 0.96, P < .001).
| Discussion |
|---|
|
|
|---|
Effects of ACE inhibition on functional recovery during postcardioplegic reperfusion
ACE inhibition improves the cardioprotective effects of crystalloid cardioplegic solutions.
1,2 In accordance with this, ACE inhibition resulted in improved developed left ventricular pressure and relaxation during postcardioplegic reperfusion in our study. However, in contrast to previous studies in isolated hearts,
2,16,17 we found no effect of captopril on myocardial blood flow, indicating that the captopril-induced alterations in myocardial metabolite exchange are independent of myocardial blood flow.
Effects of ACE inhibition on glutamate and glucose metabolism during postcardioplegic reperfusion
Glutamate plays an important role for energy metabolism in the ischemic myocardium (Fig 3, A ).
18,19 Clinical trials demonstrating increased glutamate uptake in patients with coronary artery disease
20,21 yield additional support for the importance of glutamate under conditions of ischemia. These studies showed a close relationship between myocardial carbohydrate metabolism and glutamate exchange by a positive correlation between glucose and glutamate uptake in patients with ischemic heart disease.
21 In addition, we have demonstrated that glutamate enrichment during reperfusion improves postcardioplegic recovery.
22 In the present study, captopril induced a massive glutamate release during postcardioplegic reperfusion. We have previously observed a substantial loss of glutamate from pig hearts at the start of reperfusion after cold crystalloid cardioplegia.
23 However, the glutamate release in captopril-treated hearts increased approximately 11-fold compared with that found in control hearts.
|
Myocardial glucose uptake is enhanced up to 3-fold during reperfusion after hypoxia.
24,25 Glucose is transformed to both acetyl coenzyme A and the citric acid cycle intermediate oxaloacetate (Fig 3
, B ).
26 In captopril-treated hearts we found increased uptake of glucose, which supplies the citric acid cycle with both acetyl coenzyme A and oxaloacetate, enabling the heart to oxidize larger amounts of glucose. Thus the improvement in developed left ventricular pressure and relaxation seems to be caused by a captopril-induced enhancement of glucose oxidation.
Effects of captopril during prolonged cardioplegic storage
A number of substrates are converted into oxidizable intermediates during ischemia. As a consequence of anaerobic breakdown of glycogen, lactate accumulates and glutamate is transaminated to alanine, which also accumulates in the cytosol.
8,27,28 This is in accordance with our findings of decreasing tissue content of glycogen, adenosine triphosphate, and glutamate and increasing tissue content of lactate and alanine during 30 hours of cardioplegic storage. More important, captopril had no effect on any of the measured metabolites during storage. In particular, we found no glutamate accumulation, which could explain the massive glutamate release at the start of reperfusion. The effects of captopril demonstrated in the present study are therefore strictly related to the reperfusion period. The glutamate release at the start of reperfusion in captopril-treated hearts is most likely caused by metabolic modulation, as described above.
In conclusion, the present study demonstrates that the cardioprotective properties of captopril in connection with cardioplegia and reperfusion are strictly related to the reperfusion period. The study further demonstrates that captopril increases glutamate release during reperfusion after cardioplegic storage. We suggest that this is caused by increased myocardial glucose uptake, which enhances anaplerosis of citric acid cycle intermediates and enables increased glucose oxidation in captopril-treated hearts during reperfusion.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |